Among Beam’s multiple base editing programs are BEAM-101, an ex vivo autologous hematopoietic stem cell-based gene therapy for the treatment of severe sickle cell disease (SCD), and BEAM-302, an in vivo gene editing therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). 

Beam is looking for a highly motivated individual to join the Product & Portfolio Strategy (PPS) team from July through December 2024.  The PPS team shapes the corporate and program strategy at Beam and works closely with colleagues across functions, e.g. Medical Affairs, Clinical Development, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, Program Management. The intern will contribute to projects and workstreams that are critical to the success of our lead programs and of new opportunities, such as market research, marketing strategy, competitive and financial analyses, launch planning.

Responsibilities:

• Support commercialization workstreams for BEAM-101; the specific workstream(s) will consider the candidate’s background, experiences, and interests
• Evaluate potential new opportunities for Beam by collecting and analyzing intelligence (e.g., on products, competitors, market drivers) in the gene therapy space, including engagement of Key Opinion Leaders (KOLs)
• Conduct high-level financial opportunity forecasting
• Synthesize and present information  

Qualifications:

• Pursuing one (or more) of the following graduate degrees: MBA, PhD, PharmD, MPH
• Interested in business aspects of biotechnology and drug development; prior (internship) experience in biotech companies, consulting, or in venture funding highly preferred
• Ability to think strategically and innovatively
• A strong and clear communicator, making the complex clear
• Strong interpersonal skills
• Experience with PowerPoint, Excel required